In a review published in Health Nanotechnology, researchers evaluated how explainable artificial intelligence frameworks can help overcome the persistent challenge of delivering nucleic acids to organs beyond the liver using lipid nanoparticles. The authors emphasize that delivering extrahepatic lipid nanoparticles remains a major obstacle in nanomedicine due to complex biological barriers, an incomplete understanding of underlying in vivo mechanisms, and a pronounced liver-biased biodistribution. Although artificial intelligence and machine learning predictive models have advanced rapidly, most existing tools are constrained because they rely on small, heterogeneous datasets and function as opaque systems lacking interpretability.
To address the limitations of black-box prediction, the review demonstrates that explainable artificial intelligence can uncover actionable design rules by pinpointing the specific roles of formulation parameters in organ-selective delivery. The authors identify key variables that govern delivery outcomes, including lipid chemistry, polyethylene glycol density, nanoparticle particle size, and manufacturing conditions. By shifting the computational focus from raw predictive scores to interpretable mechanisms, these models can help researchers generate structured hypotheses to inform the rational design of lipid nanoparticle systems rather than relying on unguided empirical trials.
The review outlines several model interpretation methodologies that can be used to interrogate complex algorithms and extract mechanistic insights. Specifically, the authors discuss the application of SHapley Additive exPlanations, Local Interpretable Model-agnostic Explanations, partial dependence analysis, and counterfactual reasoning to understand model behavior. These explainability techniques provide visibility into how subtle changes in lipid composition or physical particle characteristics influence carrier transport, allowing formulation scientists to evaluate the relative importance of individual parameters and establish verifiable relationships between nanocarrier chemistry and target tissue accumulation.
A primary objective highlighted in the review is the development of selective design rules capable of directing lipid nanoparticles carrying messenger RNA or small interfering RNA away from hepatic clearance toward specific non-hepatic tissues. The authors place particular emphasis on targeting possibilities for the spleen, lung, and bone marrow as primary extrahepatic targets, while also evaluating other emerging anatomical sites. They note that computational models offer a promising way to search vast chemical and biological parameter spaces far more rapidly and efficiently than manual screening.
Despite these computational opportunities, the review underscores substantial translational obstacles that currently restrict the development of artificial intelligence for extrahepatic nanomedicine. The authors point out critical bottlenecks, including widespread dataset fragmentation, a persistent lack of experimental standardization, missing descriptive metadata, and an overall scarcity of high-quality extrahepatic delivery data. Furthermore, inherent biological complexity and experimental variability make it difficult to achieve reliable, reproducible organ-specific delivery in vivo, preventing predictive algorithms from translating seamlessly into dependable experimental systems.
To bridge these translational gaps, the authors propose a comprehensive development roadmap for future explainable artificial intelligence-guided lipid nanoparticle research. This framework consists of standardized multimodal data collection, multimodal computational modeling, robust explainability tools, and iterative laboratory experiments designed specifically for biological validation. The authors stress that moving beyond predictions requires establishing design rules that are rigorously interpretable, transferable across platforms, and experimentally testable in biological settings, ensuring that machine learning models reflect genuine physiological processes rather than statistical artifacts.
Ultimately, the review concludes that explainable artificial intelligence represents more than an incremental technical improvement to machine learning algorithms, serving instead as a vital step toward mechanistically motivated and translationally accountable nanomedicine engineering. By uniting predictive computational modeling with empirical biological validation, explicit awareness of uncertainty, and regulatory alignment, researchers can work toward overcoming the current translational bottlenecks. The authors note that this integrated strategy offers a viable pathway to engineer safer, more rational, and clinically impactful nucleic acid delivery platforms in future nanomedicine.
Regarding the study’s scope and design, the authors clarify in their data availability declaration that data sharing is not applicable because no original datasets were generated or analyzed during the review. Rather than presenting new empirical trials, the paper serves as a comprehensive synthesis of the field, examining how machine learning can systematically explore vast biological and formulation parameter spaces. The authors note that while computational modeling and formulation engineering have advanced considerably, nucleic acid transport to non-hepatic tissues remains one of the least addressed challenges in lipid nanoparticle research due to lingering uncertainties surrounding in vivo particle behavior.
To translate computational findings into practical nanomedicine, the proposed framework highlights the necessity of aligning algorithmic models with regulatory standards and clinical safety requirements. The authors underscore that artificial intelligence cannot rely solely on mathematical optimization; instead, it must generate transferable design rules that can be confirmed through iterative experimental testing. By incorporating regulatory considerations and biological validation directly into the modeling pipeline, researchers can ensure that emerging delivery strategies remain robust, reproducible, and translationally accountable across diverse therapeutic applications.
Subject of Research: Explainable artificial intelligence in extrahepatic lipid nanoparticle design
Article Title: Beyond the liver: explainable AI for organ-selective lipid nanoparticle design in nucleic acid delivery
Article References: Farghama, K., Khan, M. S., Wajid, M., Shaffique, S., Khan, M. U., Umar, A., & Farooq, S. S. (2026). Beyond the liver: explainable AI for organ-selective lipid nanoparticle design in nucleic acid delivery. Health Nanotechnology, 2(1), Article 19. https://doi.org/10.1186/s44301-026-00043-7
Image Credits: AI Generated
DOI: 10.1186/s44301-026-00043-7
Keywords: lipid nanoparticles, explainable artificial intelligence, nucleic acid delivery, extrahepatic delivery, machine learning, spleen targeting, lung targeting, bone marrow targeting, SHAP, LIME, partial dependence analysis, counterfactual reasoning, polyethylene glycol density, nanoparticle size, lipid chemistry, messenger RNA, small interfering RNA, biodistribution
News Source: Blake Davidson. (November 17, 2026). Review outlines explainable artificial intelligence for targeted extrahepatic lipid nanoparticle delivery. Scienmag.



